AI in Breast Imaging: New BreastCT.com Article Examines IzoView’s Competitive Edge
Izotropic (OTCQB: IZOZF) has published a new article on BreastCT.com highlighting the competitive advantages of its IzoView Breast CT Imaging System in AI-integrated breast imaging. The article emphasizes IzoView's purpose-built design for artificial intelligence integration, featuring a proprietary reconstruction algorithm and compression-free scanning capability that delivers high-quality 3D images in just 10 seconds.
The system, targeted at a USD $500K price point, addresses growing demand for advanced breast screening solutions, particularly for dense breast tissue. IzoView's architecture combines exclusive AI capabilities with scalable software features, positioning it as a future-ready platform in the evolving landscape of intelligent medical imaging.
["Purpose-built design for AI integration with proprietary reconstruction algorithm", "Fast 10-second compression-free scanning capability", "Competitive USD $500K target price point", "Specifically addresses dense breast tissue screening challenges"]Izotropic (OTCQB: IZOZF) ha pubblicato un nuovo articolo su BreastCT.com che mette in evidenza i vantaggi competitivi del proprio IzoView Breast CT Imaging System nell’imaging mammario integrato con Intelligenza Artificiale. L’articolo sottolinea il design mirato all’integrazione dell’IA, dotato di algoritmo di ricostruzione proprietario e della capacità di scansione senza compressione, che consente immagini 3D di alta qualità in soli 10 secondi.
Il sistema, pensato per un prezzo di $500K USD, risponde alla crescente domanda di soluzioni avanzate di screening mammario, in particolare per tessuto mammario denso. L’architettura di IzoView combina capacità IA esclusive con funzionalità software scalabili, posizionandolo come una piattaforma pronta per il futuro nel panorama in evoluzione dell’imaging medico intelligente.
[Obiettivo di prezzo competitivo di USD 500K, progettazione su misura per integrazione IA con algoritmo di ricostruzione proprietario, scansione compressione-free di 10 secondi, affronta le sfide dello screening del tessuto denso]
Izotropic (OTCQB: IZOZF) ha publicado un nuevo artículo en BreastCT.com que resalta las ventajas competitivas de su IzoView Breast CT Imaging System en la imagenología mamaria integrada con IA. El artículo enfatiza el diseño específico para la integración de inteligencia artificial, con un algoritmo de reconstrucción propietario y la capacidad de escaneo sin compresión que entrega imágenes 3D de alta calidad en solo 10 segundos.
El sistema, dirigido a un precio de $500K USD, atiende la creciente demanda de soluciones avanzadas de cribado de mama, particularmente para tejido mamario denso. La arquitectura de IzoView combina capacidades de IA exclusivas con características de software escalables, posicionándolo como una plataforma lista para el futuro en el panorama de la imageneología médica inteligente.
[Diseño a medida para la integración de IA con algoritmo de reconstrucción propietario, capacidad de escaneo sin compresión de 10 segundos, precio objetivo competitivo de USD 500K, aborda específicamente los desafíos de cribado en tejido mamario denso]
Izotropic (OTCQB: IZOZF)가 BreastCT.com에 새로운 기사를 게시하여 IzoView Breast CT Imaging System의 AI 통합 유방 영상에서의 경쟁 우위를 강조했습니다. 기사에서는 인공지능 통합을 위해 특화된 설계와 독점 재구성 알고리즘, 압축 없는 스캔 기능을 강조하여 단 10초 만에 고품질의 3D 이미지를 제공합니다.
이 시스템은 미화 50만 달러(USD $500K)의 가격대에서 고도화된 유방 선별 솔루션에 대한 증가하는 수요를 해결하며 특히 찐층 유방 조직에 대한 screening을 다룹니다. IzoView의 아키텍처는 독점 AI 기능과 확장 가능한 소프트웨어 기능을 결합하여 지능형 의료 이미징의 진화하는 환경에서 향후 대비된 플랫폼으로 자리매김합니다.
[AI 통합을 위한 맞춤 설계와 독점 재구성 알고리즘, 10초 압축 없이 스캔 가능한 속도, 경쟁력 있는 USD 500K 가격대, 조밀한 유방 조직 스크리닝 문제를 구체적으로 다룸]
Izotropic (OTCQB: IZOZF) a publié un nouvel article sur BreastCT.com mettant en lumière les avantages compétitifs de son IzoView Breast CT Imaging System dans l’imagerie mammaire intégrée à l’IA. L’article met l’accent sur un design spécialement conçu pour l’intégration de l’IA, doté d’un algorithme de reconstruction propriétaire et d’une capacité de panne d’imagerie sans compression qui délivre des images 3D de haute qualité en seulement 10 secondes.
Le système, destiné à un prix d’environ $500K USD, répond à la demande croissante de solutions avancées de dépistage mammaire, en particulier pour les tissus mammaires denses. L’architecture d’IzoView combine des capacités IA exclusives à des fonctionnalités logicielles évolutives, le positionnant comme une plateforme prête pour l’avenir dans le paysage en évolution de l’imagerie médicale intelligente.
[Conception adaptée à l’intégration de l’IA avec algorithme de reconstruction propriétaire, capacité de balayage sans compression de 10 secondes, prix cible compétitif de USD 500K, aborde spécifiquement les défis du dépistage des tissus mammaires denses]
Izotropic (OTCQB: IZOZF) hat einen neuen Artikel auf BreastCT.com veröffentlicht, der die Wettbewerbsvorteile seines IzoView Breast CT Imaging System in der KI-integrierten Brustbildgebung hervorhebt. Der Artikel betont das speziell für die KI-Integration konzipierte Design, verfügt über einen eigene Rekonstruktionsalgorithmus und eine kompressionsfreie Scanzeile, mit der hochwertige 3D-Bilder in nur 10 Sekunden geliefert werden.
Das System, das zu einem Preis von rund $500K USD angeboten wird, spricht die wachsende Nachfrage nach fortschrittlichen Brustscreening-Lösungen an, insbesondere für dichtes Brustgewebe. Die Architektur von IzoView kombiniert exklusive KI-Fähigkeiten mit skalierbaren Softwarefunktionen und positioniert es als zukunftsfähige Plattform im sich entwickelnden Umfeld der intelligenten medizinischen Bildgebung.
[Auf Design ausgerichtet für KI-Integration mit proprietärem Rekonstruktionsalgorithmus, 10-Sekunden-kompressionsfreies Scannen, wettbewerbsfähiger Preis von USD 500K, adressiert gezielt Screening-Herausforderungen bei dichtem Brustgewebe]
Izotropic (OTCQB: IZOZF) نشرت مقالة جديدة على BreastCT.com تسلط الضوء على المزايا التنافسية لـ IzoView Breast CT Imaging System في التصوير الثدّي المدعوم بالذكاء الاصطناعي. تؤكد المقالة التصميم المخصص لـدمج الذكاء الاصطناعي، مع خوارزمية إعادة الإعمار المملوكة وميزة فحص بدون ضغط التي تقدم صوراً ثلاثية الأبعاد عالية الجودة في غضون 10 ثوانٍ.
النظام، المستهدف بسعر يقارب $500K USD، يعالج الطلب المتزايد على حلول فحص الثدي المتقدمة، خاصةً بالنسبة لأنسجة الثدي الكثيفة. تجمع بنية IzoView بين قدرات AI حصرية وميزات برمجية قابلة للتوسع، مما يضعه كمنصة جاهزة للمستقبل في مشهد التصوير الطبي الذكي المتطور.
[تصميم مطور لدمج AI مع خوارزمية إعادة الإعمار الملكية، إمكانية فحص بدون ضغط خلال 10 ثوانٍ، سعر هدف تنافسي قدره USD 500K، يعالج تحديات فحص النسيج الثديي الكثيف]
Izotropic (OTCQB: IZOZF) 已在 BreastCT.com 上发布了一篇新文章，强调其 IzoView Breast CT Imaging System 在 AI 融入的乳腺成像中的竞争优势。文章强调该系统专门为人工智能集成而设计，具备 专有重建算法 以及 无压缩扫描 能力，能够在仅10秒内提供高质量的3D图像。
该系统的目标定价约为 $500K USD，满足对先进乳腺筛查解决方案日益增长的需求，尤其是对致密乳腺组织的筛查。IzoView 的架构将独有的 AI 功能与可扩展的软件特性相结合，使其成为在不断发展的智能医学成像领域中面向未来的平台。
[专为 AI 集成打造的设计，具备专有重建算法；10 秒无压缩扫描能力；竞争性 USD 500K 价格； 专门应对致密乳腺组织筛查挑战]
- None.
- None.
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce the publication of a new feature article on BreastCT.com titled “AI Is Reshaping Breast Imaging, and IzoView Was Built for What Comes Next.”
The article is the latest addition to BreastCT.com, Izotropic’s growing educational content platform developed to support the Company’s commercialization strategy, raise awareness of its flagship device, the IzoView Breast CT Imaging System, and define its leadership in the emerging category of AI-integrated breast imaging.
As global demand accelerates for advanced screening solutions, particularly in patients with dense breast tissue, this article highlights why legacy systems fall short and how IzoView was purpose-built for the future of intelligent imaging.
Key takeaways from the article include:
- AI Is Improving Breast Cancer Detection at Scale
Global studies and new FDA-approved tools confirm AI boosts accuracy and speeds up diagnosis, setting the stage for a new standard in imaging. - Outdated Imaging Systems Limit AI's Full Potential
Most AI tools are retrofitted onto legacy breast imaging systems that can struggle with dense breast tissue, but they can't overcome the fundamental limitations of the hardware. - IzoView Was Designed Specifically for AI-Driven Imaging
With a proprietary reconstruction algorithm, true 3D hardware, and compression-free scans, IzoView delivers ultra-high-quality images in just 10 seconds. - A Protected Platform with Built-In Advantage
IzoView combines exclusive AI capabilities, a USD$500 K target price, and scalable software features, positioning it as a future-ready platform, not just a device.
To read the full article, visit: https://breastct.com/artificial-intelligence
About Izotropic:
More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
Email: jgagnon@izocorp.com
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
What are the key features of Izotropic's IzoView Breast CT Imaging System (IZOZF)?
How does IzoView (IZOZF) address the challenges of dense breast tissue imaging?
What is the target price for Izotropic's IzoView breast imaging system?
How does IzoView's AI integration differ from other breast imaging systems?
